Close Menu

News / Events

EGeen International Completes Another Clinical Trial Recruitment Ahead of Schedule

MOUNTAIN VIEW, CA – Following successful clinical trial approvals, EGeen International, Inc., working in close collaboration with Retrotope, Inc., the study sponsor, completed the patient enrolment in the multicenter Phase 2 clinical trial evaluating RT001 in patients with progressive supranuclear palsy ahead of schedule: Link

Progressive supranuclear palsy (PSP) is a rare yet devastating disease with no current effective treatment options. RT001 is an isotopically stabilized, synthetic linoleic acid developed by Retrotope to down-regulate lipid peroxidation, a hallmark of many neurodegenerative diseases including PSP.

EGeen International, Inc. is known for its rapid, cost-effective IntelligenTrials® clinical trial management platform geared towards agile biopharmaceutical companies.

For more information, please visit www.egeeninc.com.
Retrotope is a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for degenerative diseases ranging from orphan neurodegenerative indications to large market degenerative conditions. The company leverages its proprietary drug discovery platform to create novel, disease-modifying drugs designed to combat the oxidative stress and cellular degeneration that arises from lipid peroxidation (LPO). It does so through the creation of isotopically stabilized synthetic versions of polyunsaturated fatty acids (PUFAs) that trigger the downregulation of the LPO process. The company’s lead development candidate, RT001, is a clinical-stage isotopically stabilized, synthetic linoleic acid (LA) that is in development for a range of orphan neurodegenerative diseases, including infantile neuroaxonal dystrophy (INAD), Friedreich’s ataxia (FA), amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) and progressive supranuclear palsy (PSP). In addition, the company is advancing its second development candidate, RT011, an isotopically stabilized, synthetic docosahexaenoic acid (DHA), toward the clinic for the treatment of dry age-related macular degeneration (AMD). For more information, please visit www.retrotope.com

Read More >

August 11, 2021

EGeen International Completes Clinical Trial Recruitment Ahead of Schedule

MOUNTAIN VIEW, CA – Following successful clinical trial approvals, EGeen International, Inc., working in close collaboration with Retrotope, Inc., the study sponsor, completed the patient enrolment in the multicenter Phase 2 clinical trial evaluating RT001 in patients with amyotrophic lateral sclerosis in ahead of schedule: https://www.retrotope.com/completion-of-enrollment-in-phase-2-study-of-rt001-in-als.

Amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) is a rare yet devastating disease with no current effective treatment options. RT001 is an isotopically stabilized, synthetic linoleic acid developed by Retrotope to down-regulate lipid peroxidation, a hallmark of many neurodegenerative diseases including ALS.

EGeen International, Inc. is known for its rapid, cost-effective IntelligenTrials® clinical trial management platform geared towards agile biopharmaceutical companies.

For more information, please visit www.egeeninc.com.

Retrotope is a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for degenerative diseases ranging from orphan neurodegenerative indications to large market degenerative conditions. The company leverages its proprietary drug discovery platform to create novel, disease-modifying drugs designed to combat the oxidative stress and cellular degeneration that arises from lipid peroxidation (LPO). It does so through the creation of isotopically stabilized synthetic versions of polyunsaturated fatty acids (PUFAs) that trigger the downregulation of the LPO process. The company’s lead development candidate, RT001, is a clinical-stage isotopically stabilized, synthetic linoleic acid (LA) that is in development for a range of orphan neurodegenerative diseases, including infantile neuroaxonal dystrophy (INAD), Friedreich’s ataxia (FA), amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) and progressive supranuclear palsy (PSP). In addition, the company is advancing its second development candidate, RT011, an isotopically stabilized, synthetic docosahexaenoic acid (DHA), toward the clinic for the treatment of dry age-related macular degeneration (AMD).

For more information, please visit www.retrotope.com.

Read More >

May 5, 2021

J.P. Morgan 37th Annual Healthcare Conference

EGeen representatives will be meeting future and present clients during the J.P. Morgan Conference in San Francisco on January 7-9, 2019.

Read More >

January 7-9, 2019

EGeen International Clinical Trial Services Result in Akorn ANDA Approval

MOUNTAIN VIEW, CA. – Following a successful clinical trial executed by EGeen International, Inc., its’ client, Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, recently received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration for diclofenac sodium topical gel, 1%.

Diclofenac sodium topical gel, 1% is indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the knee and hand joints. Diclofenac sodium topical gel, 1% has not been evaluated for use on the spine, hip, or shoulder.

EGeen’s trial result was notable as one of the first clinical trial successes in bringing a generic diclofenac product to the market using the WOMAC pain scale clinical endpoint study. The trial was completed under timeline and within the project budget.

EGeen International, Inc. is known for its’ Generic Drug Development (GDD) Program, leveraging the cost effective European trial environment to support worldwide filings and approvals of generic pharmaceutical products.

Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois; Somerset, New Jersey; Amityville, New York; Hettlingen, Switzerland and Paonta Sahib, India that manufacture ophthalmic, injectable and specialty sterile and non-sterile pharmaceuticals. Additional information is available on Akorn’s website at www.akorn.com.

Read More >

November 28, 2018

J.P. Morgan 36th Annual Healthcare Conference

EGeen representatives will be meeting future and present clients during the J.P. Morgan Conference in San Francisco on January 8-11, 2018.

Read More >

January 8-11, 2018

Laguna Biotech CEO Forum - Laguna Beach, CA

The CEO of EGeen International, Inc. , Dr. Kalev Kask, will be attending the upcoming Laguna Biotech CEO Forum in Laguna Beach, CA. Dr. Kask will be among leading biopharma CEOs as they discuss the current state and future direction of the biopharmaceutical industry.

Read More >

October 8-10, 2017

BIO 2017 Conference - San Diego, CA

EGeen International, Inc. attended and exhibited at the annual BIO conference held this year in San Diego, CA. EGeen management and representatives presented their latest clinical trial program updates and met industry colleagues in Booth No. 5648.

Read More >

June 17-22, 2017

DIA 2016 Conference – Philadelphia, PA

EGeen, Inc. will be attending and exhibiting at the upcoming DIA Conference on June 26-29, 2016. EGeen representatives will be discussing the company’s newest clinical trial programs at Booth No. 2440.

Read More >

June 26-29, 2016

DCAT week - New York City

EGeen representatives will be meeting future and present clients during the DCAT week in New York City on March 15 -17, 2016.

Read More >

March 1, 2016

Akorn Inc. Study Enrollment

EGeen has completed patient enrolment on time for Akorn, Inc.'s large clinical bioequivalance study.

Read More >

February 7, 2016